1.
Effect of selenium supplementation on CD4+ T-cell recovery, viral suppression and morbidity of HIV-infected patients in Rwanda: a randomized controlled trial
by Kamwesiga, Julius
AIDS (London), 2015, Vol.29 (9), p.1045-1052
2.
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
by Fonner, Virginia A
AIDS (London), 2016, Vol.30 (12), p.1973-1983
3.
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, plac...
by Kim, Sung-Bae
The lancet oncology, 2017, Vol.18 (10), p.1360-1372
4.
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double...
by Lee, Nancy Y
The lancet oncology, 2021, Vol.22 (4), p.450-462
5.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
by le Roux, Carel W, Prof
The Lancet (British edition), 2017, Vol.389 (10077), p.1399-1409
6.
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial
by Torrico, Faustino
The Lancet infectious diseases, 2018, Vol.18 (4), p.419-430
7.
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled...
by Sulkowski, Mark, Prof
The Lancet infectious diseases, 2013, Vol.13 (7), p.597-605
8.
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial
by Koh, Christopher, Dr
The Lancet infectious diseases, 2015, Vol.15 (10), p.1167-1174
9.
Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age
by Halstead, Scott B
Vaccine, 2017, Vol.35 (47), p.6355-6358
10.
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial
by Bernstein, David I
Vaccine, 2015, Vol.34 (3), p.313-319
11.
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial
by Huttner, Angela, MD
The Lancet infectious diseases, 2015, Vol.15 (10), p.1156-1166
12.
Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalatio...
by Beigel, John H
The Lancet infectious diseases, 2018, Vol.18 (4), p.410-418
13.
Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy
by Gutiérrez, Carolina
AIDS (London), 2016, Vol.30 (9), p.1385-1392
14.
Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine
by Glenn, Gregory M
Vaccine, 2012, Vol.31 (3), p.524-532
15.
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
by Marty, Francisco M, Dr
The Lancet infectious diseases, 2011, Vol.11 (4), p.284-292
16.
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial
by Delany-Moretlwe, Sinead
The Lancet infectious diseases, 2018, Vol.18 (11), p.1241-1250
17.
The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials
by Zhang, W
Annals of the rheumatic diseases, 2008, Vol.67 (12), p.1716-1723
18.
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
by Pol, Stanislas, Dr Prof
The Lancet infectious diseases, 2012, Vol.12 (9), p.671-677
19.
20.
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus , is safe and immunogenic in healthy adults
by Schmidt, Clint S
Vaccine, 2012, Vol.30 (52), p.7594-7600
